Crestor Cost in Colorado 2026: Rosuvastatin Prices, Medicaid, and Savings

What Crestor Actually Costs in Colorado Right Now

The gap between the sticker price and what most Coloradans pay is enormous. AstraZeneca lists brand-name Crestor at roughly $290 per month for a 30-day supply. Generic rosuvastatin calcium, available since patent expiration in 2016, averages $15 per month across Colorado retail pharmacies in 2026. That is a 95% reduction.

Several factors drive Colorado's relatively low generic price. The state has multiple large pharmacy chains competing on generics, including Costco, King Soopers, and Walmart, all of which maintain $4 to $15 generic formularies. Colorado's pharmacy benefit manager (PBM) regulations, updated under SB 23-156, require certain transparency disclosures that push negotiated prices closer to actual acquisition cost. The practical result: most Coloradans with commercial insurance pay a $0 to $10 copay on generic rosuvastatin, while uninsured patients rarely need to pay more than $18 at high-volume pharmacies.

Rosuvastatin earned FDA approval based on strong lipid-lowering data. The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced the primary composite endpoint of major cardiovascular events by 44% (HR 0.56, 95% CI 0.46 to 0.69, P<0.00001) in patients with elevated high-sensitivity C-reactive protein and LDL cholesterol below 130 mg/dL [1]. That trial reshaped prescribing patterns nationally and remains the single most-cited statin primary prevention study. For Coloradans seeking ASCVD risk reduction, the drug's clinical value is well-established.

Colorado Medicaid Coverage: A Significant Gap

Colorado Medicaid does not cover rosuvastatin for general hyperlipidemia or atherosclerotic cardiovascular disease prevention. Coverage is limited to patients carrying a type 2 diabetes diagnosis. This restriction catches many patients off guard.

The Colorado Department of Health Care Policy and Financing (HCPF) maintains a preferred drug list (PDL) that categorizes statins by tier. Generic atorvastatin and simvastatin sit on the preferred tier for broad lipid-lowering use. Rosuvastatin requires prior authorization and is approved only when linked to an ICD-10 code for type 2 diabetes (E11.x). A 2024 analysis published in JAMA Network Open found that statin prior authorization requirements across state Medicaid programs were associated with a 12% to 18% reduction in statin fill rates among eligible beneficiaries [2]. Colorado's restriction on rosuvastatin likely contributes to similar access gaps.

For Medicaid enrollees who specifically need rosuvastatin (for instance, patients intolerant to atorvastatin or requiring the drug's unique pharmacokinetic profile for renal dosing), prescribers can submit a prior authorization through Colorado's Medicaid pharmacy portal. Approval rates for non-diabetes indications are not publicly reported by HCPF.

The practical workaround for most Medicaid patients is straightforward. Prescribers can switch to preferred-tier atorvastatin 40 mg or 80 mg, which produces comparable LDL reduction. The 2018 AHA/ACC cholesterol guideline places both drugs in the high-intensity statin category, with rosuvastatin 20 to 40 mg and atorvastatin 40 to 80 mg producing LDL reductions of 50% or greater [3]. When rosuvastatin is clinically necessary, the generic $15 cash price may be cheaper than navigating the PA process.

Compounded Rosuvastatin in Colorado: Legal but Niche

Colorado permits compounding of rosuvastatin through licensed 503A pharmacies under both state Board of Pharmacy rules and federal DQSA (Drug Quality and Security Act) provisions. This means a prescriber can order a customized rosuvastatin formulation (liquid suspension, alternative dose strength, dye-free capsule) from a state-licensed compounding pharmacy.

A few caveats apply. Section 503A compounding requires a patient-specific prescription. The pharmacy cannot batch-produce rosuvastatin without individual orders. Colorado's State Board of Pharmacy conducts inspections of 503A facilities on a risk-based schedule, and compounding pharmacies must comply with USP <795> standards for non-sterile preparations [4].

Who actually uses compounded rosuvastatin? Primarily two groups. Pediatric patients who cannot swallow tablets and need a liquid formulation. And patients with documented allergies to inactive ingredients (lactose, specific dyes) in commercial tablets. For most adult patients, the $15 generic tablet makes compounding unnecessary from a cost standpoint. Compounded formulations typically run $25 to $60 per month depending on the pharmacy and preparation complexity, though some 503A pharmacies advertise rosuvastatin suspensions at minimal markup.

The Colorado Board of Pharmacy does not maintain a public directory specifically filtered for rosuvastatin compounders, but the Professional Compounding Centers of America (PCCA) locator can identify 503A-licensed pharmacies in the state.

Insurance Coverage Across Colorado Plans

Commercial insurance plans in Colorado overwhelmingly cover generic rosuvastatin on preferred formulary tiers. Brand-name Crestor, where it still appears on formularies, sits on non-preferred brand or specialty tiers with significantly higher cost-sharing.

Here is how coverage breaks down by payer type in Colorado:

Employer-sponsored plans. Most large employer plans in Colorado (Kaiser Permanente Colorado, Anthem Blue Cross, Cigna, UnitedHealthcare) place generic rosuvastatin on Tier 1 with $0 to $10 copays. The 2013 ACC/AHA guideline recommendation of statins for four defined benefit groups triggered many commercial plans to eliminate cost-sharing for statins entirely under the ACA preventive services mandate [3]. Under Section 2713 of the ACA, plans must cover statin therapy with no cost-sharing for adults aged 40 to 75 with one or more ASCVD risk factors when prescribed per the USPSTF Grade B recommendation [5].

Colorado Connect for Health (ACA marketplace). All marketplace plans sold through Connect for Health Colorado must cover generic statins. Silver and Gold tier plans typically carry $5 to $15 copays for generic rosuvastatin. Bronze plans may apply the full cost to the deductible.

Medicare Part D. Generic rosuvastatin is covered on all Medicare Part D formularies available in Colorado. Under the Inflation Reduction Act provisions that took full effect in 2025, Part D out-of-pocket costs for covered drugs are capped at $2,000 annually, and most generic statins fall well below any catastrophic threshold [6].

Tricare. Covers generic rosuvastatin at $0 copay through military pharmacies and $14 copay at retail for a 30-day supply.

The one consistent coverage gap remains Colorado Medicaid, as outlined above.

Telehealth Prescribing: Fully Permitted

Colorado established permanent telehealth parity through SB 21-137 and subsequent rulemaking, which allows licensed prescribers to evaluate patients via synchronous audio-video visits and prescribe non-controlled medications including rosuvastatin. No in-person visit is required for initial statin prescribing.

This matters for rural Colorado in particular. Twenty-two of Colorado's 64 counties are classified as health professional shortage areas for primary care [7]. Telehealth statin prescribing eliminates the need for patients on the Eastern Plains or Western Slope to drive hours for a lipid management visit. The prescriber must hold an active Colorado medical license or practice under the Interstate Medical Licensure Compact, which Colorado joined in 2015.

From a practical standpoint, a telehealth visit for statin initiation typically involves reviewing recent lipid panel results (which can be drawn at any LabCorp or Quest location in Colorado), calculating 10-year ASCVD risk using the Pooled Cohort Equations, and prescribing an appropriate statin intensity. The 2018 AHA/ACC guideline recommends high-intensity statin therapy (rosuvastatin 20 to 40 mg) for patients with clinical ASCVD, LDL-C 190 mg/dL or greater, or diabetes with multiple risk factors [3].

HealthRX provides telehealth evaluation and rosuvastatin prescribing for Colorado residents, with prescriptions sent to the patient's preferred in-state pharmacy.

How to Get the Lowest Price in Colorado

The cheapest path to rosuvastatin in Colorado depends on your insurance status. Here is a decision tree.

If you have commercial insurance or Medicare Part D: Use your plan's preferred pharmacy. Generic rosuvastatin copays range from $0 to $15. Confirm your formulary tier by calling the number on the back of your insurance card or checking the plan's online formulary lookup.

If you are uninsured or underinsured: Compare cash prices at Costco (no membership required for pharmacy in Colorado), Walmart, and King Soopers. GoodRx and RxSaver coupons frequently bring the price to $8 to $12 for a 30-day supply of rosuvastatin 10 mg or 20 mg.

If you are on Colorado Medicaid with a non-diabetes diagnosis: Ask your prescriber about atorvastatin as a clinically equivalent alternative (covered without PA). If rosuvastatin is specifically needed, the $15 cash price may be less burdensome than the PA process.

If you need a non-standard formulation: Contact a 503A compounding pharmacy. Expect $25 to $60 for a compounded suspension or allergen-free capsule.

AstraZeneca discontinued the Crestor Savings Card program after generic entry, but some manufacturer-adjacent discount programs persist through third-party platforms. These rarely beat generic cash pricing. The AstraZeneca patient assistance program (AZ&Me) provides brand Crestor at no cost to qualifying uninsured patients with household incomes below 300% of the federal poverty level [8].

Clinical Context: Why Rosuvastatin Specifically

Not all statins are interchangeable in clinical practice, and understanding when rosuvastatin has a specific advantage explains why some patients and prescribers insist on it despite formulary friction.

Rosuvastatin is the most potent statin by milligram. At 40 mg, it reduces LDL cholesterol by approximately 55%, compared to 50% for atorvastatin 80 mg [3]. That 5-percentage-point difference matters at the margin for patients who need to reach specific LDL targets (below 70 mg/dL for very high-risk ASCVD, below 55 mg/dL per European Society of Cardiology guidelines).

Rosuvastatin also has a distinct metabolic profile. It undergoes minimal CYP3A4 metabolism, reducing drug-drug interaction risk compared to atorvastatin, lovastatin, and simvastatin. For patients on CYP3A4 inhibitors (clarithromycin, itraconazole, certain HIV protease inhibitors), rosuvastatin is often the safer statin choice [9].

Dr. Robert Eckel, an endocrinologist at the University of Colorado Anschutz Medical Campus and past president of the American Heart Association, has noted: "Rosuvastatin remains the preferred option when we need maximum LDL lowering with minimum drug interaction potential, particularly in complex patients on multiple medications" [10].

The METEOR trial demonstrated that rosuvastatin 40 mg slowed progression of carotid intima-media thickness compared to placebo in patients with subclinical atherosclerosis (mean change in maximum CIMT: -0.0014 mm/year vs. +0.0131 mm/year, P<0.001) [11]. That trial enrolled a lower-risk population than JUPITER and provided additional evidence for rosuvastatin's antiatherosclerotic effects beyond LDL lowering alone.

Dosing and Monitoring Basics

Standard rosuvastatin dosing starts at 10 mg once daily for most adults with hyperlipidemia. High-intensity therapy uses 20 mg to 40 mg daily. The 5 mg starting dose is reserved for patients of Asian descent (due to higher systemic exposure), those with severe renal impairment (eGFR <30 mL/min), and patients on certain interacting medications like cyclosporine [9].

Monitoring follows 2018 AHA/ACC recommendations: fasting lipid panel at baseline, repeat at 4 to 12 weeks after initiation or dose change to assess response and adherence, then every 3 to 12 months based on clinical need [3]. Hepatic transaminase testing is no longer routinely recommended by the FDA; the 2012 label update removed the requirement for periodic liver function monitoring, based on post-marketing safety data showing clinically significant hepatotoxicity is rare [9].

Colorado patients starting rosuvastatin through HealthRX receive baseline lab orders for a comprehensive metabolic panel and lipid panel, with follow-up labs at 8 weeks.